Mutations in Duchenne muscular dystrophy (DMD) are either inducing a nonsense codon or a frameshift. Meganucleases (MGNs) can be engineered to induce double-strand breaks (DSBs) at specific DNA sequences. These breaks are repaired by homologous recombination or by non-homologous end joining (NHEJ), which results in insertions or deletions (indels) of a few base pairs. To verify whether MGNs could be used to restore the normal reading frame of a dystrophin gene with a frameshift mutation, we inserted in a plasmid coding for the dog m-dystrophin sequences containing a MGN target. The number of base pairs in these inserted sequences changed the reading frame. One of these modified target m-dystrophin plasmids and an appropriate MGN were then transfected in 293FT cells. The MGN induced micro-deletion or micro-insertion in the m-dystrophin that restored dystrophin expression. MGNs also restored m-dystrophin expression in myoblasts in vitro and in muscle fibers in vivo. The mutation of the targeted m-dystrophin was confirmed by PCR amplification followed by digestion with the Surveyor enzyme and by cloning and sequencing of the amplicons. These experiments are thus a proof of principle that MGNs that are adequately engineered to target appropriate sequences in the human dystrophin gene should be able to restore the normal reading frame of that gene in DMD patients with an out-of-frame deletion. New MGNs engineered to target a sequence including or near nonsense mutation could also be used to delete it.
Introduction
Duchenne muscular dystrophy (DMD) is a hereditary disease caused by mutations of the dystrophin gene, which leads to a premature termination of the dystrophin protein due to the presence of a nonsense mutation or a frameshift mutation that results in a premature stop codon. These truncated dystrophin proteins cannot integrate into the dystrophin complex, leading to the absence of this protein under the sarcolemma. 1, 2 In contrast, deletions within the dystrophin gene, which maintain the reading frame, give rise to either asymptomatic subjects or Becker muscular dystrophy, in which the internally deleted form of dystrophin (with its aminoand carboxy-terminal ends intact) is present under the sarcolemma. Becker muscular dystrophy is usually less severe than DMD; indeed, some patients were reportedly able to walk with a cane until age 65 years. 3 There are currently several therapeutic avenues being pursued for DMD. (1) In vivo gene therapy with adeno-associated virus vectors, 4-8 using a m-dystrophin to protect the muscle fibers. 9 The main drawbacks of this therapy are that the m-dystrophin gene may not fully replace the full-length dystrophin in humans, and also the potential immune response against the adenoassociated virus capsids and risks of random integration.
(2) Transplantation of muscle precursor cells to introduce in muscle fibers normal nuclei containing the normal dystrophin gene. [10] [11] [12] [13] [14] [15] We have shown that this restored the expression of dystrophin in up to 34% of the muscle fibers. 14, 15 This strategy requires multiple injections because of inefficient migration of myoblasts and immunosuppression to prevent rejection. (3) Pharmacologic rescue of a nonsense dystrophin mutation using PTC124, a potential approach for 13-15% of DMD patients, would require a life-long administration of the drug. 16, 17 (4) Exon skipping aims to restore the translation of carboxy-terminal expression in patients with an out-of-frame deletion or a nonsense mutation by bypassing one or several exons. [18] [19] [20] This will convert DMD patients into Becker-type patients. Its drawbacks are the requirement for a life-long administration of the exon-skipping oligos and the potential long-term toxicity of these non-degradable oligonucleotides.
Gene targeting is the ultimate tool for genetic modifications for eventually treating a variety of genetic diseases, but its use is often limited by its low efficiency. In a number of recent studies, site-specific DNA double-strand breaks (DSBs) have been used to induce efficient gene targeting in chosen genes. [21] [22] [23] Meganucleases (MGNs), also called homing endonucleases, are sequence-specific endonucleases that recognize unique large (412 bp) target sites in living cells. 24 They can induce site-specific DSBs, and thereby stimulate homologous recombination of up to 10 000-fold in cultured cells. 25, 26 MGNs were used to induce homologous recombination in a variety of cell types and organisms, including mammalian cells, mice, plants, Drosophila, Escherichia coli and trypanosome. 27, 28 MGN-induced DSB can also be repaired by non-homologous end-joining (NHEJ), an error-prone process, which frequently results in micro-insertions or micro-deletions (indels) at the site of the break. 29 Engineering highly specific, dedicated DNA endonucleases is the key to a wider usage of this technology. Several groups have developed methods to locally engineer natural MGNs, [30] [31] [32] and a combinatorial approach allowing for the complete redesign of the MGN DNA-binding interface has been described. 33 Finally, two engineered MGNs cleaving two different human genes, XPC and RAG1, have been described in the literature. 21, [33] [34] [35] These recent developments provide the potential to target any chromosomal locus with engineered MGNs. Thus, these proteins represent a universal tool to mutate the genome at specific sequence target and are thus very promising for precise and efficient genome modifications.
Our article suggests that specifically engineered MGNs, with their capability to introduce with high efficiency indels at a specific site within a specific gene, could eventually be used to restore the reading frame of dystrophin mutations that cause frameshift alterations. The use of such specifically engineered MGNs would represent a novel approach to treat not only DMD but also several other genetic diseases, as this approach could also be used to delete nonsense mutations in any gene.
Results

Specific targets for RAG1 and I-SceI within the m-dyst/V5
The MGNs, RAG1 and I-SceI, were under control of a modified elongation factor-1a (EF1a) gene promoter fused to exon 1 and intron 1 of EF1a gene (Figure 1a) . The MGN complementary DNAs (cDNAs) were preceded at their 5 0 end by nucleotides coding for the hemagglutinin (HA) tag and for a nuclear localization signal. The expected molecular weight for MGNs RAG1 and I-SceI with the HA tag and the nuclear localization signal were 42.3 and 31.2 kDa, respectively. The transcription unit of RAG1 and I-SceI were contained in a plasmid size of 5.51 and 5.15 kb, respectively.
A sequence of 28 or 25 nucleotides including the specific MGN target for RAG1 or I-SceI MGNs was inserted within the m-dystrophin/V5 (m-dyst/V5) cDNA near the NheI site, as described in Figure 1b , creating m-dyst RAG1 /V5 or m-dyst IÀSceI /V5. The insertion of this sequence in the m-dyst/ V5 cDNA changed the reading frame of the part of the dystrophin gene that is located after the inserted sequence; this resulted in the presence of several premature stop codons. The wild-type and the mutated m-dyst/V5 were under a cytomegalovirus promoter and were introduced in a plasmid pLenti6/V5 containing a puromycin gene resistance. A wild-type m-dyst/V5 (Figure 1b ) without an MGN target insertion was used as control to evaluate the efficiency of m-dystrophin expression in our analysis system.
Expression of m-dystrophin after co-transfection of an appropriate MGN plasmid with the corresponding m-dystrophin target plasmid
We developed a plasmid-based gene repair assay involving the two components (a plasmid target and an MGN plasmid), as described in Figures 1a and b , to verify the capacity of an MGN to modify the reading frame of m-dyst RAG1 /V5 or m-dyst IÀSceI /V5, leading to some expression of the mutated m-dyst/V5. In 293FT cells, m-dyst RAG1 /V5 or m-dyst IÀSceI /V5 was co-transfected with the corresponding MGN plasmid. At 28 h after transfection, the total proteins were extracted from the cells, to be analyzed by western blot, using an anti-V5 antibody to detect the expression of m-dyst/V5 and a goat antibody against the HA tag to detect the expression of the MGN protein. As expected, the presence of m-dyst/V5 (molecular weight of 175 kDa) and of the MGN RAG1 (Figure 2a, lanes 1-4) or of the MGN I-SceI (Figure 2b, lanes 1-4) were detected by western blot analysis in the protein extracts. As expected, m-dyst/V5 was more strongly expressed when the MGN co-transfection was performed with a higher amount of target plasmid (1200 ng; Figures 2a and b, lanes 3 and 4) than with a lower amount of target plasmid (200 ng; Figures 2a and b, lanes 1 and 2) . However, a reduced amount of MGN had no effect on the m-dyst/V5 expression (lanes1 and 2 with I-SceI. In both these experiments, the 100% value was determined by nucleofecting cells with the same amount of the m-dyst/V5 plasmid without an inserted sequence to change the reading frame. Both these results indicated that the correction of the m-dyst/V5 target gene was substantial.
In a subsequent experiment, the V5 tag was replaced with an EGFP gene to create m-dyst/EGFP (normal reading frame) and m-dyst RAG1 /EGFP (with a 28-bp insert for the RAG1 target modifying the reading frame). These plasmids were then transfected in 293FT cells either alone or with the RAG1 MGN. After 2 days, the cells were analyzed with the fluorescent microscope and by fluorescence-activated cell sorting for the expression of m-dyst/EGFP. The m-dyst/EGFP plasmid was expressed in only 5. MGNs can restore the reading frame of a mutated dystrophin P Chapdelaine et al changed the reading frame of that transgene, resulting in the presence of nonsense codons. The first of these nonsense codons (that is, a TAG) is underlined in Figures  1b2 and b3 . However, this is not the only nonsense codon that results from such a frameshift mutation, as there are several other stop codons along the m-dystrophin transgene. It is thus surprising to observe the presence of green fluorescence in 0.7% 293FT cells transfected only with the target m-dyst RAG1 /EGFP target without the plasmid coding for the MGN (Figure 2e) . A possible interpretation of this result is that they may be because of the insertion in the cell genome of the eGFP sequence (part of the m-dyst RAG1 /EGFP plasmid) after a promoter leading to expression in these cells. However, 6.6% cells expressed m-dyst/EGFP when the cells were co-transfected with the target plasmid (m-dyst RAG1 /EGFP) and the RAG1 plasmid (Figures 2c and d) . These results indicate that RAG1 re-established the reading frame of m-dyst RAG1 /EGFP in a high percentage of the cells that were effectively transfected with the target plasmid. This, however, does not mean that the reading frame was restored in all the target plasmids, as there were many copies in each transfected cells. In Figure 2c , some of the cells may be undergoing apoptosis. This is a phenomenon that we have observed in the past in myoblasts expressing micro-dystrophin or dystrophin. (a) The expression of both MGNs, RAG1 (a1) and I-SceI (a2), is driven by a mutated translation elongation factor-1a (EF-1a) promoter. The transcription unit is composed mainly of the presence of exon 1 and intron 1 of EF-1a gene fused to MGN cDNA harboring a HA tag and a nuclear localization signal (NLS) at the N-terminal whereas SV40 polyadenylation site (SV40 polyA) is present in C-terminal after stop codon. (b) Plasmids containing the dog m-dyst/V5 are represented under three different constructs. The first construct (b1) is the wild-type m-dyst/V5 without target insertion (m-dyst/V5). The GCTAGC represent the Nhe1 restriction enzyme site coding for amino acids alanine (A) and serine (S) (which are underlined). The second construct (b2) and the third construct (b3) contain insertions (sequences in red) near of the NheI site. These insertions are 28 bp in b2 and 25 bp in b3, resulting in both cases in an out-of-frame expression of m-dyst/V5 and creating stop codons (the first one TAG is underlined). The inserted sequences included the specific target (nucleotide box) for RAG1 (mdyst RAG1 /V5) and I-SceI (m-dyst IÀSceI /V5). The HCSQVPQPAC-HGKTKQFT-SSNGSPE and HARDNRVIC-HGKTK represent, respectively, the beginning of the amino acid changes for mutated dog m-dyst/V5 constructs containing a target for RAG1 or I-SceI.
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The expression of these proteins in proliferating cells seems to be toxic. This is why it is better to express these proteins under a muscle-specific promoter so that they are expressed only in myotubes and muscle fibers, which are non-proliferating. Because of this apoptosis, the percentage of restoration of the microdystrophin reading frame may be underestimated in that experiment.
Mutation detection by Surveyor enzyme of episomal plasmid mutated m-dyst/V5 in 293FT cells treated with the MGNs RAG1 or I-SceI
We tried to confirm that the expression of the m-dyst/V5 after co-transfection of the target plasmid and of the MGN plasmid was really because of the modification by the MGN endonuclease activity of the target sequence inserted in the mutated m-dyst/V5. A DSB induced by the MGN can be repaired by an error-prone NHEJ and the resulting DNA often contains small insertions within the cleavage site or deletions around the cleavage position ('indel' mutations). To confirm the presence of indels in the episomal-targeted plasmids, the DNA of the transfected cells (including the episomal target plasmid) was extracted and amplified by PCR using primers located within the m-dyst/V5 gene before and after the MGN target nucleotide sequence, as described in the Materials and methods section. In vitro, the indels can be detected by treatment of amplified DNA fragments (amplicons) with mismatch-sensitive Surveyor endonuclease according to the protocol described in the Sequencing of the targeted area confirmed the presence of indels and the restoration of the reading frame for MGN RAG1
We next wanted to confirm not only the presence of indels but also the presence of indels that restored the normal reading frame of the m-dyst RAG1 /V5 plasmid. The preparation of DNA from 293FT cells co-transfected with 1200 ng of target m-dyst RAG1 /V5 and 2.8 mg of MGN RAG1 has been described in the Materials and methods MGNs can restore the reading frame of a mutated dystrophin P Chapdelaine et al . This is the reason why the upper band is a doublet. This mixture of amplicons was heated at 95 1C to permit the formation of homodimers and heterodimers. Only the heterodimers were cut by the Surveyor enzyme producing fragments (the two lower bands). The schema in c comparing the mutated dog m-dyst/V5 with the wild-type dog m-dyst/V5 explains that the size differences of the fragments generated by the Surveyor enzyme are because of the insertion of sequence including the specific target for MGNs (black box) located near of the NheI site. These inserted sequences were 28 bp for RAG1 and 25 bp for I-SceI (see Figure 1 ). Note the correspondence between the restoration of the expression of dystrophin observed by western blot (Figures 2a and b , lanes 1 and 2 or 3 and 4) and the cleavage by Surveyor enzyme of a hetero/homoduplex in Figure 3 (panels a and b, lanes 2 or 3). These observations confirm the specificity of MGNs RAG1 and I-SceI for their own target present in mutated m-dyst/V5 constructs.
MGNs can restore the reading frame of a mutated dystrophin P Chapdelaine et al section. The amplicons generated by PCR amplification of this DNA were cloned in DH5a and sequenced. As presented in the Figure 4a , indels were detected in 6 of the 15 clones randomly picked (thus, 40% of targets were mutated). Moreover, four of these clones (27% of total clones) had indels that restored the reading frame (amino acids sequence; Figure 4b ) of the m-dyst RAG1 /V5 transgene. This shows that NHEJ was able to efficiently restore the expression of an out-of-frame mutated dystrophin within 293FT cells.
Restoration of m-dystrophin reading frame in muscle fibers
All the previous experiments have been performed in 293FT cells because they are easy to transfect. However, for an eventual clinical application, it is the dystrophin gene located in muscle fibers that will have to be targeted. Will MGN induce indels in muscle fibers? To answer this question, m-dyst/V5, m-dyst RAG1 /V5 or m-dyst IÀSceI /V5 were electroporated either alone or with the plasmid coding for the appropriate MGN (that is, either RAG1 or I-SceI) in tibialis anterior muscles of Rag/mdx mice. After 2 weeks, the mice were killed and the tibialis anterior muscles were prepared for immunohistochemistry analysis of the m-dyst/V5 expression as described in the Materials and methods section. In the negative controls (electroporated the target plasmid m-dyst RAG1 /V5 or m-dyst IÀSceI /V5 alone), the expression of the V5-tag was detected in the membrane of rare weakly labeled muscle fibers (Figure 5a ). The fluorescence was restricted to the muscle fibers and can thus not be attributed to a random integration of the V5 tag. A possible interpretation is that there have been spontaneous deletions in some of the electroporated m-dyst RAG1 /V5 plasmids that have restored the reading frame. In the positive control (that is, muscles electroporated with the m-dyst/V5 plasmid), the expression of m-dystrophin was detected in abundant muscle fibers (Figure 5b ). Finally, in the muscles that were co-electroporated with m-dyst RAG1 /V5 or m-dyst IÀSceI /V5 and with the plasmid coding for the appropriate MGN, the co-electroporations led to the restoration of the normal m-dystrophin reading frame and thus to its presence in many muscle fibers (see Figure 5c for RAG1 and Figure 5d for I-SceI). Figure 5e summarizes which the reading frame of m-dyst RAG1 /V5 was restored by indels induced by RAG1 (note that in each of them some amino acids (underlined) differed from the wild-type m-dyst/V5 because of the remaining portion of the inserted sequence). In two clones (lines 6 and 7), the reading frame of m-dyst RAG1 /V5 was modified by the mutations induced by RAG1 but their amino acid sequences did not correspond to the wild-type m-dyst/V5 sequence because the correct reading frame was not restored by the micro-deletion (line 6) or the micro-insertion (line 7).
MGNs can restore the reading frame of a mutated dystrophin P Chapdelaine et al the results obtained with the two MGNs at three concentrations (that is, 0, 10 and 20 mg). For both MGNs, there were more V5-tag-positive fibers when the ratio of MGN plasmid to the targeted plasmid was higher. The DNA was extracted from the electroporated muscles 2 weeks after the electroporation and the plasmid region targeted by the MGN I-SceI was amplified. The amplicons were then digested with the Surveyor enzyme. The presence of two additional bands ( Figure 6 ) are because of the presence of some heteroduplexes that were cut by the Surveyor enzyme, confirming that the I-SceI MGN had mutated the m-dystrophin target plasmid. Figure 5 Direct intramuscular co-electroporation in muscle fibers of a mutated dog m-dyst/V5 plasmid containing an MGN target and of an MGN plasmid restored m-dyst/V5 expression in vivo. In this figure, the expression of m-dyst/V5 was detected by red immunofluorescence with an antibody against the V5 tag. As a negative control in a, m-dyst RAG1 /V5 was electroporated alone in the muscle, and only rare weakly labeled muscle fibers were detected 2 weeks later. As a positive control in b, the wild-type m-dyst/V5 plasmid was electroporated alone in the muscle. Abundant muscle fibers expressed in the V5 tag were present. (c) m-dyst RAG1 /V5 was co-electroporated with the RAG1 plasmid, and abundant muscle fibers expressed the V5 tag. (d) m-dyst IÀSceI /V5 was co-electroporated with the I-SceI plasmid, and abundant muscle fibers expressed the V5 tag. (e) Summary for both MGNs at two different concentrations of the total numbers of dystrophin/V5 muscle fibers observed in 10 sections collected throughout the muscles at 150 mm intervals. Scale bars are 50 mm in a-d.
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Mutations by MGNs RAG1 and I-SceI of a m-dystrophin gene integrated in myoblast genome
Lentivirus vectors containing under the cytomegalovirus promoter and either m-dyst/V5, m-dyst RAG1 /V5 or m-dyst IÀSceI /V5 were made. These lentiviruses also contained a puromycin-resistance gene under a SV40 promoter. They were used to infect human myoblasts. The infected cells were selected with puromycin and proliferated for 2 weeks. Afterward, the selected myoblasts were nucleofected with a plasmid coding either for the RAG1 or the I-SceI MGN. Control myoblasts were not nucleofected with the MGN. After 3 days, the DNA was extracted from all myoblasts. The m-dystrophin region containing the targeted sequences for RAG1 or I-SceI was amplified by PCR. As the infected myoblasts have been proliferated, it is only the transgenes that were integrated in the cell genome that were amplified. These amplicons were then digested with the Surveyor enzyme to verify the presence of heterodimers due to indels produced by the MGN in the m-dyst/V5 gene integrated in the cell genome. Figure 7a (lanes 3 and 4) illustrates the results of the Surveyor enzyme reactions. As a positive control, amplicons obtained from cells containing the transgene m-dyst RAG1 /V5 or m-dyst IÀSceI /V5 were mixed together in different proportions (1 to 1, 5 to 1 and 10 to 1). This generated roughly 50, 20 and 10% of heterodimers. These mixtures were then digested with the Surveyor enzyme generating digested bands of different intensities proportional to the percentages of heterodimers (Figure 7a , lanes 5-7). The intensity of the bands in lanes 3 and 4 compared with those of lanes 5-7 suggested that the MGNs were able to mutate 10-20% of the m-dystrophin genes integrated in the myoblast genome.
Discussion
MGNs can restore the reading frame of a frameshift mutation efficiently
Statistically, two-thirds of the indels introduced by MGNinduced error-prone NHEJ should shift the reading frame of coding sequence (that is, these alterations will be of lengths that are not multiples of 3 bp); thus, we envisioned that one out of three indels would restore the reading frame of out-of-frame deletions. Our results clearly showed that indeed the reading frame of a transgene can be restored by such a process. Indeed, two different MGNs were used in our experiments and both of them restored the reading frame of the m-dystrophin gene with an out-of-frame deletion. The restoration of the reading frame was substantial, as indicated by several different tests. Indeed, the western blot indicated that the corrections of m-dystrophin target plasmids were 13% with I-SceI (Figure 2b , lane 4) and 30% with RAG1 ( Figure 2a, lane 4) . The experiments with m-dyst RAG1 / EGFP led to expression of m-dyst/EGFP in 100% of the transfected cells. The Surveyor enzyme reaction confirmed in the same cells that the target plasmids were mutated by RAG1. Furthermore, the cloning and sequencing of PCR products encompassing the cleavage site region confirmed that the reading frame was restored in 27% of the clones. The percentage of restoration of the reading frame probably depends on the MGNs used and the experimental conditions. The present experiments showed that MGNs were able to mutate an episomal as well as an integrated m-dystrophin gene. These results are a proof of principle that MGNs could be used to restore the normal reading frame of the dystrophin gene in patients with a deletion, which results in a frameshift of the resulting mRNA.
It is however important to point out that the experiments presented in this paper have been performed in very favorable conditions. Indeed, in 293FT cells the plasmid coding for the target gene as well as the MGN expression plasmid were transfected into the cells. Thus, there were certainly many copies (perhaps hundreds) of both plasmids, favoring the mutation of the target plasmids. In fact, our experiments indicated that between 27 and 46% of the target plasmids were mutated. Abundant copies of the target plasmids and MGN plasmids were also co-electroporated in the Figure 6 Restoration of m-dystrophin expression in muscle fibers is due to mutations of the targeted plasmids. Various plasmids were electroporated in mouse muscles: in lane 1, two plasmids m-dyst IÀSceI /V5 and I-SceI were co-electroporated in the muscles; in lane 2, only the m-dyst/V5 was electroporated; and in lane 3, only the m-dyst IÀSceI /V5 plasmid was electroporated. The DNA was extracted from these muscles 15 days later and the region targeted by the MGN I-SceI was amplified. The amplicons were then digested with the Surveyor enzyme. The higher band at 683 bp is the uncut m-dyst IÀSceI /V5 plasmid. The presence of two additional bands in lane 1 is because of the cutting of the m-dyst IÀSceI /V5 plasmid by the Surveyor enzyme because of the presence of some heteroduplexes confirming that the I-SceI MGN had induced indels in the m-dystrophin target plasmid. Lane 4 is a positive control for the Surveyor enzyme reaction; that is, the amplicons obtained from myoblasts nucleofected with m-dyst IÀSceI /V5 were mixed with amplicons obtained from myoblasts nucleofected with m-dyst RAG1 /V5. As heterodimers were formed the Surveyor enzyme cut the amplicons.
MGNs can restore the reading frame of a mutated dystrophin P Chapdelaine et al experiment performed in muscle fibers. Similarly, in the experiment with myoblasts, although the target m-dystrophin gene was incorporated in the genome, there may have been several copies integrated in each cell genome, thus favoring the genetic modification of at least one of these target transgenes. Hence, it is not possible to know whether the heteroduplex, or protein expression that is seen as end product, correspond to the restoration of one, a few or several target genes in given cells. Moreover, the integration sites were probably different and some of these sites may have been more accessible to the MGN protein. Thus, future experiments will have to be performed with MGNs targeting the real dystrophin gene.
Targeting the endogenous dystrophin gene
Although the RAG1 MGN described in this study has been shown to induce efficient gene targeting in the endogenous hRag1 gene in human cells, 21 it is used in this study on a model reporter system. In future experiments, it will be necessary to use MGNs that are specific for a given sequence of the dystrophin gene. MGNs targeting the DMD gene have been engineered recently (F Pâques, personal communication) and could be used to provide further proof of concept of our current approaches.
To restore the reading of the real dystrophin gene, the indels, however, would have to be induced at the end of the exon that precedes the out-of-frame deletion so that they do not induce a new stop codon within the modified exon. Alternatively, the indels could be induced at the beginning of the exon that follows the out-of-frame deletion in the sequence that precedes the first stop codon induced by the frameshift deletion. As with exon-skipping strategies currently being pursued, the resulting protein would have intact amino-and carboxyterminal sequences. Such variants might therefore be expected to have at least partial activity, as is the case in Becker Muscular dystrophy patients. It is important to note that in contrast to exon-skipping strategies, dystrophin alterations induced by MGNs would be permanent because the DNA rather than the mRNA is targeted and therefore would not require repeated treatments.
In addition, it is important to point out that for a therapeutic effect, it will not be necessary to mutate the dystrophin gene in every nuclei in the muscles fibers. Indeed, we have previously shown that the presence of only one nucleus containing a normal dystrophin gene was able to restore the expression of dystrophin in MGNs can restore the reading frame of a mutated dystrophin P Chapdelaine et al over 500 mm of the fiber (a section containing at least 500 nuclei). 36 As for the exon-skipping therapy of DMD, there are some patients who will not be treatable by restoration of the reading frame by NHEJ induced by the MGN because their deletion is too big or contain an essential dystrophin segment. In addition, it might be difficult to engineer MGNs targeting the appropriate sequence, when the distance between the mutation and the next stop codon is very short. For these patients, it may however be possible to correct their dystrophin gene by HR after a double-strand cut of the gene. This approach, however, would require the presence of a donor sequence that would have to be introduced in the cells in addition to the MGN. This will require an adequate vector to deliver both components to the cells in vitro or in vivo.
Potential genotoxicity of MGNs
One of the potential downsides of the technology is that MGNs could potentially cleave off-target sequences, resulting in toxicity. The presence of many mutations and/or gross chromosomal rearrangements 37 at offtarget sites would probably induce the death of the treated cells, a problem that we have not observed so far in our experiments. Former studies have shown that the RAG1 MGN used in this study showed reduced toxicity, if any. 21 However, for therapeutic applications, such studies, essentially based on the monitoring of histone H2AX phosphorylation (an early cellular response to DSB production) 38 and cell survival assays, need to be completed with a panel of surveys, including genomic and animal model studies, 39 and similar studies will have to be conducted with MGNs targeting the DMD gene to validate their therapeutic potential
Future directions (clinical application)
It is clear that the clinical application of MGNs to treat DMD will take several years of additional research. However, the data presented in this study provide a proof of principle for a new therapeutic avenue, which can eventually be applied not only to DMD but eventually also to many other hereditary diseases.
For a clinical application, the main issue remains the delivery of the MGN. One potential solution would be to use an adeno-associated virus vector. However, this would require a systemic delivery of this vector and the production of this vector in good manufacturing practice condition. Moreover, the expression of the MGN would eventually have to be turned off. An alternative could be the coupling the MGN to a protein transduction domain to enter the muscle fibers. This strategy could alleviate the need for viral vectorization, and could form the basis of a novel therapeutic approach, based on the systemic delivery of proteins for treating not only DMD but also many other genetic diseases. Proteins can nowadays be produced in good manufacturing practice conditions at relatively low cost, and one has to consider that the treatment will not have to be repeated. However, the potential immunogenicity of the MGN/protein transduction domains will have to be assessed. Nevertheless, the use of MGNs as expression vector or proteins seems to be a promising alternative to current gene therapy strategies.
Materials and methods
MGNs RAG1 and I-SceI
Functional MGNs, RAG1 and I-SceI, were a gift from Dr Frédéric Pâques (Cellectis S.A., Romainville, France) and for this study they were used as plasmids containing a transcriptional unit as described in Figure 1a . The RAG1 MGN corresponds to a single-chain I-CreI derivative previously described as scV3
Plasmid vectors containing the dog m-dystrophin fused to a V5 tag and containing an insertion including the RAG1 or I-SceI target sequence Dog m-dystrophin cDNA (3.8 kb) contained in an adeno-associated virus plasmid (gift from Dr Xiao Xiao, 40 University of Pittsburgh, Pittsburgh, PA, USA) was amplified by PCR with Phusion High-Fidelity DNA Polymerase (New England Biolabs, Pickering, Canada) and then treated for 10 min at 72 1C with Taq DNA Polymerase (New England Biolabs) and cloned in a TA cloning vector, that is, pDrive (Qiagen, Mississauga, Canada). The resulting clones were sequenced to confirm the integrity of dystrophin nucleotide sequence. The m-dystrophin cDNA was introduced in a directional TOPO vector (Invitrogen) in phase with V5 tag already present in the plasmid. The blasticidin-resistance gene in the original vector had been replaced with a puromycinresistance gene. The final construct of dog m-dystrophin cDNA fused in C-terminal with the V5 tag is the WILD-TYPE m-dyst/V5 (Figure 1b) . A unique SalI restriction site has been added to the 5 0 of this dog m-dyst/V5 cDNA. The presence of a unique NheI site present at position 1312 within the m-dyst/V5 cDNA permitted us to introduce by PCR a 28-bp sequence (in red in Figure 1b ) including the specific target site for RAG1: 5 0 -GTTCTCAGGTACCTCAGCCA-3 0 or a 25-bp sequence including the specific target site for I-SceI: 5 0 -CTAGGG ATAACAGGGTAA-3 0 . For this PCR, the reverse primer contained the target sequence for either RAG1 or I-SceI and an NheI restriction site and the forward primer contained an SalI restriction enzyme site. After amplification of the WILD-TYPE plasmid m-dyst/V5 with the previous primers and cloning in the pDrive vector (Qiagen), the fragment SalI/NheI (1300 bp) containing the target sequence for one of the specific MGN was sequenced and cloned in the WILD-TYPE m-dyst/V5 plasmid also cut with SalI/NheI (removing the original fragment and replacing it with the mutated fragment) and making final constructs MUTATED m-dyst/V5 containing the RAG1 (m-dyst RAG1 /V5) or I-SceI target (m-dyst IÀSceI /V5; see Figure 1b ). These mutated m-dyst/V5 constructs resulted in an out-of-frame m-dyst/V5 expression and created several stop codons, which made it impossible to express the V5 epitope peptide as shown in Figure 1b .
Episomal m-dyst/V5 gene repair in 293FT cells
For the studies of the episomal gene repair, 293FT cells were used (Invitrogen). 293FT cells were grown in Dulbecco's modified Eagle's medium high glucose, 10% bovine serum, 4 mM glutamine and 1 Â penicillin/ streptomycin. All these components were purchased from Wisent (Montreal, Canada). The 293FT cells were co-transfected in the presence of lipofectamine 2000 (Invitrogen) with 200 or 1200 ng of m-dyst RAG1 /V5 or MGNs can restore the reading frame of a mutated dystrophin P Chapdelaine et al m-dyst IÀSceI /V5. Some cells were co-transfected with the plasmid coding for the MGN RAG1 or I-SceI (Cellectis Inc., Romainville, France). The transfection with lipofectamine 2000 was performed according to the manufacturer's protocols (Invitrogen) in which the total final amount of plasmid was 4 mg, completing with specific MGNs RAG1 or I-SceI or in the absence of MGNs with pLenti6/V5 EGFP. The transfection efficiency was estimated to be near 100% in control cells transfected with a similar-sized EGFP plasmid. At 2 days after the transfection, the 293FT cells were harvested by simply detaching them by pipetting up and down, followed by several washings in phosphatebuffered saline. The cells were then divided in two pools to extract the proteins and the DNA separately from the same well. Proteins were analyzed by western blotting using specific antibodies for the V5 tag fused to mutated m-dystrophin or for the HA tag fused with the MGNs. The DNA was amplified by PCR for the identification of heteroduplex formation with the Surveyor enzyme digestion and for confirmation by cloning, and sequencing was used to verify the presence of indels after NHEJ induced by the MGNs in the 293FT cells.
In a second experiment on episomal gene repair, the V5 tag in the m-dyst RAG1 /V5 or m-dyst IÀSceI /V5 was replaced by an EGFP gene to create the fusion protein m-dyst RAG1 /EGFP or m-dyst IÀSceI /EGFP. These fusion genes were transfected in 293FT cells with lipofectamine 2000 as described previously.
Mismatch selective endonuclease assay for evaluation of MGN-mediated gene mutations
The MGNs, RAG1 or I-SceI, are able to produce mutations of their specific target located in m-dyst RAG1 / V5 or m-dyst IÀSceI /V5. These mutations were evaluated by PCR amplification of a segment of the m-dyst, which included the specific target sequence for RAG1 or I-SceI (see Figure 3c for position of the primers). DNA was extracted from 293FT cells transfected with the target mutated m-dyst/V5 with and without co-transfection with one of the MGNs. Amplicons from cells transfected with the MGNs were mixed in an equal amount with amplicons obtained from cells transfected with the target without the MGN. The amplicon mix was then denaturated and re-annealed, allowing modified target amplicon and non-modified target amplicon to re-anneal together to create heteroduplexes. The re-annealed PCR products were then digested with the Surveyor nuclease (Transgenomic, Omaha, NE, USA) that preferentially cuts DNA at sites of duplex distortions. In brief, PCR (50 ml reactions) was performed with the Phusion HighFidelity DNA Polymerase (New England Biolabs) from 100 ng of DNA extracted from 293FT in which the mutated m-dyst/V5 and one of the MGNs were present and a control (mutated m-dyst/V5 alone without the MGN). The amplification reaction with Phusion polymerase was performed (1 cycle at 98 1C for 1 min; 35 cycles at 98 1C for 10 s, at 60 1C for 30 s and at 72 1C for 30 s; and 1 cycle at 72 1C for 10 min) using the following primers: forward 5 0 -GACAGTTATCAAACAGCTTTG GAAG-3 0 (pos 1027-1051 dystrophin cDNA) and reverse 5 0 -GTAATCTGTGGGTGTCTTGTAAAAGA-3 0 (pos 1684-1673 dystrophin cDNA). The PCR products (amplicons) were extracted after electrophoresis on agarose gel 1.4% and purified with a Qiaquick gel extraction kit (Qiagen). A mix of an equal amount of two PCR products generated from DNA extracted from 293FT cells was made in 9 ml containing annealing buffer 1 Â (10 mM Tris-HCl pH 8.3, 50 mM KCl and 1.5 mM MgCl 2 ). Heteroduplex formation was allowed by heating a block in a bath at 95 1C for 5 min, removing it from bath and letting it cool by itself to o30 1C. After re-annealing, 0.5 ml of the Surveyor Enhancer S and 0.5 ml Surveyor nuclease (Transgenomic Inc.) were added to a total volume of 10 ml. The reaction was incubated at 42 1C for 20 min to digest heteroduplexes and the cleaved products were analyzed on a 2% agarose gel containing TBE 1 Â buffer (90 mM Tris/64.6 mM boric acid/2.5 mM EDTA, pH 8.3) and ethidium bromide (1 mg ml À1 ). To estimate approximately the expected fragment size generated by the Surveyor endonuclease, we mixed amplicons of the wild type of m-dyst/V5 (without target) with the mutated m-dyst/V5 produced from DNA extracted from transfected 293FT cells.
Protein extraction and western blot analysis of the m-dyst/V5 and MGNs from 293FT cells Protein extraction from 293FT cells was performed according to the previously published protocol. 41 The presence of the m-dyst/V5, RAG1 or I-SceI was confirmed by western blot of proteins extracted from the 293FT cells. Usually, an aliquot of 20 mg of proteins extracted from 293FT cells treated in different conditions was loaded in each lane and electrophoresed in 8% acrylamide gel (sodium dodecyl sulfate-polyacrylamide gel electrophoresis). The proteins were then electro-transferred onto a 0.45 mm nitrocellulose membrane (Bio-Rad, Hercules, CA, USA) and cut in two sections: the upper part (proteins range over 85 kDa) for the detection of the m-dyst/V5 and the lower part for the detection of HA tag fused with the MGN RAG1 or the I-SceI (proteins range under 85 kDa). Membrane sections were blocked in 5% (w/v) non-fat dry milk (bovine lacto transfer technique optimizer) dissolved in PBS containing 0.05% Tween-20 for 1 h and then incubated overnight at 4 1C in the presence of a primary antibody, either a monoclonal antibody directed against the V5 epitope (Invitrogen) diluted 1/5000 to detect the m-dyst/V5 or a goat polyclonal antibody against the HA tag (GenScript, Piscataway, NJ, USA) diluted 0.5 mg ml -1 to detect the HA-MGNs. After incubation of the membrane sections, three consecutive washings were performed for 10 min in PBS-Tween 0.05% and the membranes were then incubated for 1 h with a specific secondary antibody, that is, a rabbit anti-goat coupled to peroxidase (1/10 000) for the V5 tag or a rabbit anti-goat coupled to peroxidase (1/10 000) for the HA tag both in PBS-Tween 0.05% containing 5% bovine lacto transfer technique optimizer. After incubation of membrane sections with their specific secondary antibody, three washings (10 min each) were performed in PBS-Tween. The membranes were then treated for 1 min with the enhanced chemiluminescent substrate (Perkin-Elmer, Woodbridge, Canada) and exposed to a Bio-Max film (Perkin-Elmer).
Gene sequencing of mutated episomal DNA to confirm the occurrence of NHEJ in 293FT cells DNA was extracted from 293FT cells (in a six-well plate) co-transfected with 1200 ng of m-dyst RAG1 /V5 and 2.8 mg MGNs can restore the reading frame of a mutated dystrophin P Chapdelaine et al of the MGN RAG1 plasmid. A protocol to extract DNA based on the use of proteinase K, RNase and phenol/ chloroform procedure was used. 42 The total DNA, including the genomic DNA and the plasmid coding for m-dyst RAG1 /V5, was co-precipitated. The plasmid DNA was amplified with Phusion DNA polymerase using specific primers for dog dystrophin (described in Mismatch selective endonuclease section above). This amplicon was then treated with TAQ DNA polymerase (NEB) to add an adenosine nucleotide at 3 0 end of the PCR fragments to permit direct cloning in pDrive cloning vector (Qiagen) with the Qiagen PCR cloning kit. After transformation of ligation products in competent bacteria DH5a, several clones were picked up randomly to prepare plasmids (mini-prep) and sequenced with T7 primer.
Animals
Immunodeficient Rag-Mdx mice were from our own colony. Such immunodeficient mice were used to avoid immune reaction against the MGN proteins. All the experiments made with these animals were approved by the animal protection committee of the Laval University.
Electroporation
A total of 20 or 30 mg of the target plasmid (m-dyst RAG1 / V5 or m-dyst IÀSceI /V5) were co-injected, respectively, with 20 or 10 mg of an MGN (either RAG1 or I-SceI) in a final volume of 40 ml in the mouse muscle for electroporation. As a negative control, the target plasmid (20 mg) was injected alone and as positive control, 40 mg of the original m-dyst/V5 plasmid (without the MGN target) was injected alone. A single longitudinal injection was made into the tibialis anterior, and the 'Electrode Electrolyte' cream (Teca Corporation, Pleasantville, NY, USA) was applied on the skin to improve the spreading of the electric current between two metal plaques. The parameters were: 10 pulses of 200 V cm -1 , duration of 25 ms and delay of 300 ms. The electroporated muscles were harvested 2 weeks after the experiment and were rapidly frozen in liquid nitrogen. Serial 12 mm cryostat sections were prepared throughout the entire muscle.
Immunohistochemical detection of m-dyst/V5 in mouse tibialis anterior muscle
Immunohistological analyses were performed with mouse anti-V5-tag antibody (1:200; Invitrogen) followed by incubation with a biotinylated anti-mouse antibody (1:300; Dako, Mississauga, Canada) and Streptavidin-Cy3 (1:300; Sigma-Aldrich, St Louis, MO, USA). Afterwards, the sections were mounted in PBS-glycerol (1:1). The presence of GFP proteins and the immunohistological staining were observed under fluorescence using an Axiophot microscope (Zeiss, Oberkochen, Germany).
Lentivirus infection of human myoblasts, selection and proliferation followed by nucleofection with an MGN As described above, plasmid constructs pLenti6/V5 m-dyst RAG1 /V5 or m-dyst IÀSceI /V5 (3 mg each) have been transfected in the presence of pVSVG (2.8 mg), pREV (2 mg) and pGAG/POL (4.2 mg) with calcium phosphate in a 100-mm Petri dish containing 293T cells (lentivirus producers) near90% of confluence in the culture medium (Dulbecco's modified Eagle's medium high glucose, 10% bovine serum and 1 Â of penicillin/streptomycin) and the supernatant was harvested 48 h after transfection. This culture medium containing viral particles was filtered on a 0.45 mm membrane and kept at À80 1C if not used immediately. The day before the infection, 250 000 myoblasts were seeded per well in a six-well plate and cultured in the MB1 medium (Hyclone, South Logan, UT, USA). The infection of human myoblasts was performed when the cells reached near 40-50% confluence by replacing MB1 medium with 3 ml of viral supernatant from 293T cells described previously and incubated overnight at 37 1C. The next day, the viral medium was changed by 3 ml of fresh MB1 medium and these cells were proliferated for 48 h. The infected cells were then selected with puromycin at 2 mg ml -1 during 48 h and proliferated for 2 weeks. Before testing the MGNs RAG1 and I-SceI with the infected and selected human myoblasts, the presence of the target gene m-dyst RAG1 /V5 or m-dyst IÀSceI /V5 was verified by PCR amplification of the genomic DNA with the primers described in Mismatch selective endonuclease assay section. As the PCR analysis indicated the presence of the expected amplicon size, the nucleofection of infected human myoblasts was made as previously described. 43 In brief, 5 mg of plasmid MGNs RAG1 or I-SceI was introduced by nucleofection within the infected human myoblasts containing the corresponding specific target. Nucleofector solution adult (NHDF-adult) has been used and the nucleofector apparatus (AMAXA Inc., Amaxa Nucleofector System, Lonza Walkerrsville Inc., Walkersville, MD, USA) was set to program P-022 according to the Amaxa protocol. After the nucleofection of the MGN plasmid, the cells were grown for 3 days in MB1 culture medium followed by DNA extraction. The MGN target region was amplified by PCR. The resulting amplicons were treated with the Surveyor enzyme as described previously.
